Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
STAMFORD, Conn., May 02, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 9, 2018, at 4:30 p.m. ET to report first quarter 2018 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 1264618. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, CR845/difelikefalin has demonstrated efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
